The Technical Analyst
Cytokinetics Inc [CYTK]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cytokinetics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.91% $66.82
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6 987.77 mill |
| EPS: | -5.45 |
| P/E: | -12.26 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 104.58 mill |
| Avg Daily Volume: | 2.07 mill |
| RATING 2024-04-24 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -12.26 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.09x |
| Company: PE -12.26 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-9.30 (-113.92%) $-76.12 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 63.31 - 70.21 ( +/- 5.17%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-12 | Malik Fady Ibraham | Sell | 150 | Common Stock |
| 2024-04-09 | Malik Fady Ibraham | Buy | 28 605 | Common Stock |
| 2024-04-09 | Malik Fady Ibraham | Sell | 28 605 | Common Stock |
| 2024-04-09 | Malik Fady Ibraham | Sell | 4 000 | Common Stock |
| 2024-04-09 | Malik Fady Ibraham | Sell | 28 605 | Non-Qualified Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -8.51 |
| Last 100 transactions |
| Buy: 502 934 | Sell: 613 862 |
Forecast:
16:00 - $66.89
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $66.89
Forecast 2: 16:00 - $66.89
Forecast 3: 16:00 - $66.89
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $66.82 (1.91% ) |
| Volume | 0.781 mill |
| Avg. Vol. | 2.07 mill |
| % of Avg. Vol | 37.79 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CYTK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:36 | sell | $78.97 | N/A | Active |
|---|
CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-24 16:00:00 - Press Release
Cytokinetics To Announce First Quarter Results On May 8, 2024
South san francisco, calif., april 24, 2024 (globe newswire) -- cytokinetics, incorporated (nasdaq: cytk) today announced that it is scheduled to report first quarter results on may 8, 2024 at 4:00 pm eastern time. following the announcement, cytokinetics' senior management will host a conference call at 4:30 pm eastern time to discuss operational and financial results and the company's outlook for the future.
2024-04-10 07:30:00 - Press Release
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating To Sequoia-hcm At The European Society Of Cardiology Heart Failure 2024 Congress
Primary results from sequoia-hcm to elaborate on positive topline results in patients with obstructive hypertrophic cardiomyopathy
2024-04-05 07:30:00 - Press Release
Cytokinetics Presents Additional 48-week Data From Forest-hcm, The Open Label Extension Clinical Study Of Aficamten, At The American College Of Cardiology 73ʳᵈ Annual Scientific Session
Treatment with aficamten for 48 weeks is associated with improvements in clinical efficacy endpoints, nyha class and cardiac biomarkers, structure and function treatment with aficamten for 48 weeks is associated with improvements in clinical efficacy endpoints, nyha class and cardiac biomarkers, structure and function
2024-04-02 16:00:00 - Press Release
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
South san francisco, calif., april 02, 2024 (globe newswire) -- cytokinetics, incorporated (nasdaq: cytk) today announced that on march 29, 2024 it granted stock options to purchase an aggregate of 78,000 shares of common stock to five new employees, whose employment commenced in march 2024, as a material inducement to their employment.
2024-04-01 16:00:00 - Press Release
Cytokinetics To Participate In The 23rd Annual Needham Virtual Healthcare Conference
South san francisco, calif., april 01, 2024 (globe newswire) -- cytokinetics, incorporated (nasdaq: cytk) today announced that robert i. blum, president and chief executive officer, is scheduled to participate in a fireside chat at the 23rd annual needham virtual healthcare conference on monday, april 8, 2024 at 2:15 pm eastern time.
Latest News
2024-04-24 16:00:00 - GlobeNewsWire
Cytokinetics to Announce First Quarter Results on May 8, 2024
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.
2024-04-10 09:27:00 - Market Watch
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
2024-03-18 20:01:33 - InvestorPlace
7 Biotech Stocks Ready to Ride the Sector's Resurgence
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
2024-03-16 03:43:48 - Seeking Alpha
Cytokinetics: CEO Talks Down Buyout Prospects
2024-03-13 14:25:31 - InvestorPlace
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn't received the same fervor.
2024-03-04 16:00:00 - GlobeNewsWire
Cytokinetics to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March:
2024-02-27 18:11:03 - Zacks Investment Research
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to loss of $1.45 per share a year ago.
2024-02-13 16:00:00 - GlobeNewsWire
Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.
2024-02-08 09:10:29 - InvestorPlace
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to improve the quality of life of all human beings.
2024-01-12 16:32:06 - Zacks Investment Research
Cytokinetics (CYTK) Down on Report of Novartis Not Interested
Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.